The comparative study by Rotolo et al. showed that CD1d-restricted engineered CD19-CAR-NKT cells acted more effectively than CD19-CAR-T cells against CD1d-expressing lymphomas in vivo. This evidence concerns the gene CD1D and lymphoma.